Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 11, 2010, Pages 1381-1387

  Byrd, J B ^a,b   Woodard Grice, A ^a   Stone, E ^a   Lucisano, A ^a   Schaefer, H ^a   Yu, C ^a   Eyler, A E ^a   Salloum, N E ^a   Brown, N J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Angioedema; Dipeptidyl peptidase IV; Immunosuppressant; Transplant

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DIPROTIN A; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; FEMALE; GLOMERULONEPHRITIS; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; INCIDENCE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; DIPEPTIDYL PEPTIDASE 4; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 78649278976     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.02398.x     Document Type: Article

References (32)

1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G,. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
2. Pfeffer MA, Braunwald EA, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD,. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
4. Byrd JB, Adam A, Brown NJ,. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006; 26: 725-737.
5. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260: 967-970.
6. Sica DA,. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned? J Clin Hypertens (Greenwich) 2003; 5: 159-167.
7. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E,. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17: 103-111.
8. Brown NJ, Ray WA, Snowden M, Griffin MR,. Black americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60: 8-13.
9. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165: 1637-1642.
10. Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008; 51: 141-147.
11. Abbosh J, Anderson JA, Levine AB, Kupin WL,. Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Ann Allergy Asthma Immunol 1999; 82: 473-476.
12. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K,. Increased Incidence of Angioedema with ACE Inhibitors in Combination with mTOR Inhibitors in Kidney Transplant Recipients. Clin J Am Soc Nephrol 2010; 5: 703-708.
13. Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol 2007; 120: 403-408.
14. Lefebvre J, Murphey LJ, Hartert TV, Jiao SR, Simmons WH, Brown NJ,. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002; 39 (2 Pt 2): 460-464.
15. Buron F, Perrin H, Malcus C, Hequet O, Thaunat O, Kholopp-Sarda MN, et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. Transplant Proc 2009; 41: 3347-3352.
16. Gabrilovac J, Abramic M, Uzarevic B, Andreis A, Poljak L,. Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1.1 is down-regulated by dynorphin-A(1-17) as a non-substrate inhibitor. Life Sci 2003; 73: 151-166.
17. Qi SY, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO,. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J 2003; 373 (Pt 1): 179-189.
18. Rosenberg EI, Mishra G, Abdelmalek MF,. Angiotensin-converting enzyme inhibitor-induced isolated visceral angioedema in a liver transplant recipient. Transplantation 2003; 75: 730-732.
19. Mahe E, Morelon E, Lechaton S, Kreis H, De PY, Bodemer C,. Angioedema in renal transplant recipients on sirolimus. Dermatology 2007; 214: 205-209.
20. Fuchs U, Zittermann A, Berthold HK, Tenderich G, Deyerling KW, Minami K, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005; 79: 981-983.
21. Stallone G, Infante B, Di PS, Schena A, Grandaliano G, Gesualdo L, et al. Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant 2004; 19: 2906-2908.
22. Lykavieris P, Frauger E, Habes D, Bernard O, Debray D,. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. Transplantation 2003; 75: 152-155.
23. Ozdemir O, Rrey-Mensah A, Sorensen RU,. Development of multiple food allergies in children taking tacrolimus after heart and liver transplantation. Pediatr Transplant 2006; 10: 380-383.
24. Lambeir AM, Durinx C, Scharpe S, De M I,. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-294.
25. Scharpe S, DeMeester I, Vanhoof G,. Serum dipeptidyl peptidase IV activity in transplant recipients. Clin Chem 1990; 36: 984.
26. Korom S, De MI, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, et al. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997; 63: 1495-1500.
27. Emanueli C, Grady EF, Madeddu P, Figini M, Bunnett NW, Parisi D, et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998; 31: 1299-1304.
28. Campos MM, Calixto JB,. Neurokinin mediation of edema and inflammation. Neuropeptides 2000; 34: 314-322.
29. Skidgel RA,. Characterization of the metabolism of substance P and neurotensin by human angiotensin I converting enzyme and " enkephalinase". Prog Clin Biol Res 1985; 192: 371-378.
30. Ward PE, Chow A, Drapeau G,. Metabolism of bradykinin agonists and antagonists by plasma aminopeptidase P. Biochem Pharmacol 1991; 42: 721-727.
31. Ahmad S, Wang L, Ward PE,. Dipeptidyl(amino)peptidas IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther 1992; 260: 1257-1261.
32. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA,. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009; 54: 468-470.